8-nitrogen mustard phenyl-7H-purine derivative with anti-tumor activity as well as preparation method and application of 8-nitrogen mustard phenyl-7H-purine derivative

The synthesis of 8-nitromylphenyl-7H-purine derivatives was simplified through the condensation reaction, and the problem of difficulty in substitution of guanine or 2,6-diaminopurine in the prior art was solved, thus achieving anti-tumor activity The efficient preparation of strong compounds and the effect of inhibiting tumor cell proliferation.

CN118930544APending Publication Date: 2024-11-12GUANGDONG OCEAN UNIVERSITY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411222511.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to replace different groups by the 8 position of guanine or 2,6-diaminopurine, and the synthesis steps of nitrogen mustard drugs are complex, affecting the physiological properties and physiological activities of the drug.

Method used

By condensing 2,4,5,6-tetraaminopyrimidine or 2,4,5-triamino-6-hydroxypyrimidine with 4-[bis(β-chloroethyl)amino]benzaldehyde, 8- Nitromal phenyl-7H-purine derivatives simplify the synthesis steps and enhance anti-tumor activity.

Benefits of technology

It has achieved efficient preparation of 8-nitrogen-mustard phenyl-7H-purine derivatives with strong anti-tumor activity, significantly inhibiting tumor cell proliferation, and has extensive research and application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930544A_ABST
    Figure CN118930544A_ABST
Patent Text Reader

Abstract

The invention discloses an 8-nitrogen mustard phenyl-7H-purine derivative with antitumor activity as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, 2, 4, 5, 6-tetraaminopyrimidine or 2, 4, 5-triamino-6-hydroxypyrimidine and 4-[bis (beta-chloroethyl) amino] benzaldehyde are used as raw materials, and a target molecule is obtained in one step through a condensation reaction, so that on one hand, the problems of more synthesis steps and difficult separation of pyrimidine derivatives are solved; on the other hand, nitrogen mustard and pyrimidine are combined, a brand-new structure is achieved, and in-vitro anti-tumor experiments show that the synthesized target compound has an obvious anti-tumor effect, shows very high pharmacological activity in the aspect of inhibiting tumor cell proliferation and has wide research and development value in the field of anti-tumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to an 8-nitrogen mustard phenyl-7H-purine derivative with anti-tumor activity and a preparation method and application thereof. Background Art

[0002] Guanine or 2,6-diaminopurine compounds play an important role in anti-tumor, anti-viral and anti-bacterial applications. The modification of these two types of compounds is mainly at position 8. It is very difficult to directly replace different groups at position 8 of guanine or 2,6-diaminopurine. Nitrogen mustard drugs are an important class of anti-tumor substances. Their structure mainly includes bis(2-chloroethyl)amine and a carrier part. The different carrier parts connected to the carrier part have a greater impact on the overall physicochemical properties and physiological activity of the compound. Therefore, it is crucial to develop new drugs that are easy to synthesize and have strong anti-tumor activity. Summary of the invention

[0003] The purpose of the present invention is to provide an 8-nitrogen mustard phenyl-7H-purine derivative with anti-tumor activity and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.

[0004] To achieve the above object, the present invention provides the following solutions:

[0005] One of the technical solutions of the present invention is an 8-nitrogen mustard phenyl-7H-purine derivative with anti-tumor activity, the structural formula of which is

[0006] The second technical solution of the present invention is a method for preparing the 8-nitrogen mustard phenyl-7H-purine derivative, comprising the following steps: adding 2,4,5,6-tetraaminopyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde to a solvent, heating the reaction, and then purifying the product with a washing solvent to obtain the 8-nitrogen mustard phenyl-7H-purine derivative;

[0007] Alternatively, 2,4,5-triamino-6-hydroxypyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde are added to a solvent, heated for reaction, and the product is then purified by washing solvent to obtain the 8-nitrogen mustard phenyl-7H-purine derivative.

[0008] The third technical solution of the present invention is the use of the 8-nitrogen mustard phenyl-7H-purine derivative in the preparation of anti-tumor drugs, and the tumors include renal clear cell adenocarcinoma, liver cancer, breast cancer and colorectal adenocarcinoma.

[0009] A fourth technical solution of the present invention is an anti-tumor drug, comprising the 8-nitrogen mustard phenyl-7H-purine derivative.

[0010] Based on the above technical solution, the present invention has the following technical effects:

[0011] The present invention uses 2,4,5,6-tetraaminopyrimidine or 2,4,5-triamino-6-hydroxypyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde as raw materials, and obtains the target molecule in one step through a condensation reaction, which overcomes the problem of multiple synthesis steps and difficult separation of pyrimidine derivatives. On the other hand, nitrogen mustard and pyrimidine are combined to have a brand-new structure. In vitro anti-tumor experiments show that the synthesized target compounds have obvious anti-tumor effects and show strong pharmacological activity in inhibiting tumor cell proliferation, and have extensive research and development value in the field of anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0013] Figure 1 This is a graph showing the experimental results of the anti-proliferation activity of products 1a and 1b prepared in Example 1 and Example 2 of the present invention on 786-O cells.

[0014] Figure 2 This is a graph showing the experimental results of the anti-proliferation activity of products 1a and 1b prepared in Example 1 and Example 2 of the present invention on HepG2 cells.

[0015] Figure 3 This is a graph showing the experimental results of the anti-proliferation activity of products 1a and 1b prepared in Example 1 and Example 2 of the present invention on MDA-MB-231 cells.

[0016] Figure 4 This is a graph showing the experimental results of the anti-proliferation activity of products 1a and 1b prepared in Example 1 and Example 2 of the present invention on SW620 cells. DETAILED DESCRIPTION

[0017] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0018] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0019] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0020] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0021] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0022] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or have been disclosed.

[0023] The present invention provides an 8-nitrogen mustard phenyl-7H-purine derivative with anti-tumor activity, the structural formula of which is

[0024]

[0025] The embodiment of the present invention also provides a method for preparing the 8-nitrogen mustard phenyl-7H-purine derivative, comprising the following steps: adding 2,4,5,6-tetraaminopyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde to a solvent, heating the reaction, and then purifying the product with a washing solvent to obtain the 8-nitrogen mustard phenyl-7H-purine derivative;

[0026] Alternatively, 2,4,5-triamino-6-hydroxypyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde are added to a solvent, heated for reaction, and the product is then purified by washing solvent to obtain the 8-nitrogen mustard phenyl-7H-purine derivative.

[0027] In some specific embodiments, the molar ratio of the 2,4,5,6-tetraaminopyrimidine or 2,4,5-triamino-6-hydroxypyrimidine to 4-[bis(β-chloroethyl)amino]benzaldehyde is 1:1.

[0028] In some specific embodiments, the solvent is dimethyl sulfoxide.

[0029] In some specific embodiments, the heating reaction temperature is 130° C. to 160° C., and the reaction time is 5 to 12 hours.

[0030] In some specific embodiments, the washing solvent further includes the steps of suction filtration, water washing and freeze drying before purification.

[0031] In some specific embodiments, the washing solvent is a mixed solution of dichloromethane and acetone, and the volume ratio of dichloromethane to acetone is 1:3 to 1:6.

[0032] The embodiment of the present invention also provides the use of the 8-nitrogen mustard phenyl-7H-purine derivative in the preparation of anti-tumor drugs, and the tumors include renal clear cell adenocarcinoma, liver cancer, breast cancer and colorectal adenocarcinoma.

[0033] The embodiment of the present invention further provides an anti-tumor drug, comprising the 8-nitrogen mustard phenyl-7H-purine derivative.

[0034] In some specific embodiments, a pharmaceutically acceptable excipient is also included.

[0035] The present invention condenses 2,4,5-triamino-6-hydroxypyrimidine or 2,4,5,6-tetraaminopyrimidine with a formyl group and oxidizes to obtain a guanine or 2,6-diaminopurine compound substituted at position 8. Purine is combined with nitrogen mustard, and an aromatic aldehyde containing nitrogen mustard is reacted with 2,4,5-triamino-6-hydroxypyrimidine or 2,4,5,6-tetraaminopyrimidine to obtain an 8-nitrogen mustard phenyl-7H-purine derivative, which has the advantages of fewer reaction steps, simple separation, high yield, etc., and the product shows obvious effect in inhibiting tumor cell proliferation, and has wide application value.

[0036] Example 1

[0037] The structural formula of compound 1a is as follows:

[0038]

[0039] Preparation of compound 1a:

[0040] 2,4,5,6-Tetraaminopyrimidine (5 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (5 mmol) were added to dimethyl sulfoxide (60 mL) and heated at 160°C for 8 hours. The reaction solution was added to 300 mL of water, filtered, washed with water, and freeze-dried. The crude product was then washed with dichloromethane:acetone = 1:3 (V / V) to obtain product 1a.

[0041] Characterization data: 1 H NMR (600MHz, DMSO-d6)δ: 1 HNMR (400MHz, DMSO-d6), δ, ppm: 10.60 (s, 1H, OH), 7.82 (d, J = 8.96Hz, 2H, ArH), 6.78 (d, J = 8.96Hz, 2H, ArH), 6.28 (s, 2H, NH2), 3.75~3.66 (overlapped, 8H, CH2). 13 C NMR(100MHz,DMSO-d6),δ,ppm:153.77,147.95,127.88,112.29,100.04,52.39,41.63.HR-MS(ESI)m / z:Calcd for C 15 H 17 Cl2N6O[M+H] + 367.0841, found 367.0840.

[0042] Example 2

[0043] The structural formula of compound 1b is as follows:

[0044]

[0045] Preparation of compound 1b:

[0046] 2,4,5-Triamino-6-hydroxypyrimidine (5 mmol) and 4-[bis(β-chloroethyl)amino]benzaldehyde (5 mmol) were added to dimethyl sulfoxide (60 mL) and heated at 160°C for 8 hours. The reaction solution was added to 300 mL of water, filtered, washed with water, and freeze-dried. The crude product was then washed with dichloromethane:acetone = 1:3 (V / V) to obtain product 1a.

[0047] Characterization data: 1H NMR (400MHz, DMSO-d6), δ, ppm: 10.60 (s, 1H, OH), 7.82 (d, J = 8.96Hz, 2H, ArH), 6.78 (d, J = 8.96Hz, 2H, ArH), 6.28 (s, 2H, NH2), 3.75~3.66 (overlapped, 8H, CH2). 13 C NMR(100MHz,DMSO-d6),δ,ppm:125.37,14.15,111.86,68.44,58.60,53.48,41.58.HR-MS(ESI)m / z:Calcd for C 15 H 18 Cl2N7[M+H] + 366.1001, found 366.1003.

[0048] Effect example

[0049] In vitro antiproliferative activity

[0050] When the tumor cells (786-O, HepG2, MDA-MB-231 and SW620) were in the logarithmic growth phase, approximately 2 × 10 3 After 24 hours of cell attachment, 100 μM of the drug prepared in Example 1-2 diluted with 10% FBS in the culture medium was added to each well, and the cells were placed in a 37°C incubator again. After the cells were cultured for 72 hours, 25 μL MTT reagent was added to each well and incubated in the incubator for 3 hours. The culture medium in the 96-well plate was discarded, dissolved with DMSO, and the OD of each well was read by an ELISA reader. 570 The survival rate of cells after treatment with different drug concentrations was calculated.

[0051] Cell survival rate % = [(Abs 样品 -Abs 背景 ) / (Abs 阴性对照 -Abs 背景 )]×100%. Abs 样品 : Absorbance when the test compound is added; Abs 背景 : Absorbance without cells and detected compounds; Abs 阴性对照 : Absorbance without the detected compound.

[0052] The results of the antiproliferative activities of products 1a and 1b prepared in Examples 1 to 2 on 786-O, HepG2, MDA-MB-231 and SW620 cells are shown in Figures 1 to 4. As can be seen from the figure, with the increase of compound concentration, its antiproliferative ability on 786-O, HepG2, MDA-MB-231 and SW620 cells continued to increase, and all showed good antiproliferative activity. Among them, 1a and 1b compounds have the strongest antiproliferative activity on SW620 cells, with half-inhibitory concentrations of 15.8μM and 16.1μM, respectively. When the drug concentration reaches 32μM / L, the cell survival rates are only 30.5% and 31.4%, respectively; when the drug concentration reaches 64μM / L, the cell survival rates are only 15.4% and 16.6%, respectively, and the cell survival rates are greatly reduced. The inhibitory ability of 1a and 1b compounds on HepG cells is second, with half-inhibitory concentrations of 24.0μM and 22.8μM, respectively. Under the action of high concentrations (64μM / L) of compounds, the cell survival rates are only 36.5% and 25.7%. The antiproliferation ability of compounds 1a and 1b on 786-O cells is slightly lower than that on HepG2 cells, and the half-inhibitory ability is 27.5μM and 25.0μM. Finally, for MDA-MB-231 cells, the half-inhibitory concentrations of compounds 1a and 1b are 30.6μM and 25.9μM, respectively.

[0053] From the structure-activity relationship, the activities of compounds 1a and 1b are similar. In general, the activity of 1b is slightly stronger than that of 1a, that is, when the 6th position on the purine ring is a hydroxyl group (guanine), the activity is slightly better than that of the amino group. The above results show that the synthesized 8-nitrogen mustard phenyl-7H-purine derivative has obvious anti-tumor activity.

[0054] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. An 8-nitrogen mustard phenyl-7H-purine derivative with antitumor activity, having the structural formula 2. The method for preparing the 8-nitrogen mustard phenyl-7H-purine derivative according to claim 1, It is characterized in that The following steps are involved: Adding 2,4,5,6-tetraaminopyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde to a solvent, heating the mixture for reaction, and purifying the product with a washing solvent to obtain the 8-nitrogen mustard phenyl-7H-purine derivative; Alternatively, 2,4,5-triamino-6-hydroxypyrimidine and 4-[bis(β-chloroethyl)amino]benzaldehyde are added to a solvent, heated for reaction, and the product is then purified by washing solvent to obtain the 8-nitrogen mustard phenyl-7H-purine derivative.

3. The preparation method according to claim 2, It is characterized in that The molar ratio of the 2,4,5,6-tetraaminopyrimidine or 2,4,5-triamino-6-hydroxypyrimidine to 4-[bis(β-chloroethyl)amino]benzaldehyde is 1:

1.

4. The preparation method according to claim 2, It is characterized in that The solvent is dimethyl sulfoxide.

5. The preparation method according to claim 2, It is characterized in that The temperature of the heating reaction is 130° C. to 160° C., and the reaction time is 5 to 12 hours.

6. The preparation method according to claim 2, It is characterized in that The washing solvent also includes the steps of suction filtration, water washing and freeze drying before purification.

7. The preparation method according to claim 2, It is characterized in that The washing solvent is a mixed solution of dichloromethane and acetone, and the volume ratio of the dichloromethane to acetone is 1:3 to 1:

6.

8. Use of the 8-nitrogen mustard phenyl-7H-purine derivative as claimed in claim 1 in the preparation of anti-tumor drugs, It is characterized in that Such tumors include renal clear cell adenocarcinoma, liver cancer, breast cancer, and colorectal adenocarcinoma.

9. An anti-tumor drug, It is characterized in that The invention comprises the 8-nitrogen mustard phenyl-7H-purine derivative as claimed in claim 1.

10. The anti-tumor drug according to claim 9, It is characterized in that Pharmaceutically acceptable excipients are also included.

Citation Information

Patent Citations

  • 2-Amino-8-substituted guanine derivative with IKK-beta as target spot, as well as application and preparation method thereof

    CN103804380A

  • Fused heterocycle compound as Bruton kinases inhibitor

    CN104211703A

  • Aromatic heterocyclic derivatives and application thereof in medicaments

    CN104557664A

  • Influenza virus replication inhibitor and application thereof

    CN108727369A

  • N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

    US20120115915A1